Azenta Inc. (AZTA)

FairStock Score: 25/100 — RISKY

Key Financials

Strengths

• Generates $109 million in annual free cash flow (9.4% yield on market cap)
• Conservative balance sheet with debt-to-equity of just 0.03, providing financial flexibility

Concerns

• Elevated P/E of 43.3x prices in substantial future growth that may not materialize
• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions
• No meaningful dividend despite modest growth—total return depends entirely on multiple expansion

AI Analysis

Azenta Inc. is a micro-cap healthcare company valued at $1.1 billion. Revenue stands at $595 million, though the company is currently unprofitable. From a quality standpoint, Azenta shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and healthy Altman Z-Score of 3.2. On valuation, the stock is commanding a steep 43.3x multiple, with trades above its Graham Number with a negative 13% margin. Growth dynamics show revenue growing at 0.8% and profit growth of -40.4%. Our composite FairStock Score of 25/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $109 million in annual free cash flow (9.4% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

At 43x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer